Guerbet strengthens its commitment to Women’s Health

• The company will attend the 2019 RCOG World Conference in London & 
ESHRE Annual Meeting in Vienna

• Guerbet also highlights the value of Hysterosalpingography (HSG) in Infertility 

Villepinte (France), June 12, 2019 - Guerbet (FR0000032526 GBT), a global specialist of contrast agents and solutions for medical imaging, reaffirms its commitment to Women’s Health with its participation to two upcoming conferences: the Royal College of Obstetricians and Gynaecologists (RCOG) World Congress 2019, which will take place in London, from June 17 to 19, and the European Society of Human Reproduction & Embryology (ESHRE) 2019 Annual Meeting, which will be held in Vienna, from June 23 to 26. The company also highlights the value of HSG within Infertility Management.

Infertility is defined as the inability to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. It is estimated that one in six couples faces infertility1. Main causes of women infertility include Fallopian tubes abnormalities, ovulation disorders, endometriosis & unexplained infertility.

Sub-fertile couples undergo a series of fertility tests. Fallopian tubes and uterine cavity assessment is an important step within infertility workup, performed mainly by HSG procedure. HSG is endorsed by main international clinical practice guidelines (NICE: The National Institute for Health and Care Excellence, ASRM: American Society for Reproductive Medicine, FIGO: International Federation of Gynecology and Obstetrics, CFAS: Canadian Fertility & Andrology Society) as part of the overall fertility assessment 2,3,4,5. This procedure requires the injection of a contrast agent into the uterine cavity & tubes under fluoroscopy monitoring.

Beyond its diagnostic efficacy, HSG also proves pregnancy improvement for couples with unexplained subfertility compared to no HSG 6,7,8,9. The mechanism-of-action remains unclear, tubal flushing might dislodge non-occlusive debris from Fallopian tubes, also it has been suggested a possible immunobiological effect by inducing some peritoneal & endometrial immunobiological modulations helping for better endometrial bathing 6,10,11,12.

“Hysterosalpingography is the standard of care for evaluating tubal patency within Infertility Management, and we rely on the only oil-based contrast medium Lipiodol® Ultra Fluid, Guerbet’s flagship contrast agent, for tubal flushing for infertile women” explained Thomas Bonnefont, VP Commercial Interventional Imaging for Guerbet.

HSG procedure


In April 2019, the Guerbet Group launched a website dedicated to health professionals on women's health issues, including the diagnosis and treatment options of infertility and breast cancer:
1  A policy audit on fertility. Analysis of 9 EU countries. March 2017. Fertility Europe. 
2 National Institute for Health and Clinical Excellence (NICE): guidance. Fertility: assessment and treatment for people with fertility problems. Feb 2013. Ref: 213280.
3 Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015 Jun;103(6):e44-50. 
4 The FIGO Fertility Tool Box™. 201
5  Canadian Fertility & Andrology Society. CFAS consensus document for the investigation of infertility by first line physicians. Aug 2002.
6  Dreyer K et al. Reprod Biomed Online. The therapeutic effect of hysterosalpingography in couples with unexplained subfertility: a post-hoc analysis of a prospective multi-centre cohort study. 2019 Feb;38(2):233-239. Epub 2018 Dec 7.
7 (Public information website developed and funded by RSNA and ACR)
9  Mohiyiddeen L et al. Tubal flushing for subfertility. Cochrane Database Syst Rev. 2015 May 1;(5):CD003718.
10  Johnson NP et al. Hum Reprod. The FLUSH trial--flushing with Lipiodol® for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial. 2004 Sep;19(9):2043-51. Epub 2004 Jul 22.
11  Izumi G et al. Oil-Soluble Contrast Medium (OSCM) for hysterosalpingography modulates dendritic cell and regulatory T cell profiles in the peritoneal cavity: a possible mechanism by which OSCM enhances fertility. J Immunol. 2017 Jun 1;198(11):4277-4284. Epub 2017 Apr 28.

Press release

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit